NCT06437509View on ClinicalTrials.gov

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

PD-1 monoclonal antibody

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY